Bioinvent’s Rights Issue Oversubscribed

Regulatory News:

Not for release, or for publication or distribution, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zeeland or South Africa.

BioInvent International (OMXS:BINV) announced today that its new share issue of up to 10,560,826 shares with pre-emptive right for the shareholders has been oversubscribed. The subscription period was concluded on 19 July 2013. The subscription price was SEK 2.10 and BioInvent's shareholders had pre-emptive right to subscribe for one new share for every seven existing shares.

The final result of the rights issue shows that 8,428,882 shares, representing 80 per cent of the offered shares were subscribed for by the exercise of subscription rights. In addition, subscription forms in respect of 5,285,572 shares, representing 50 per cent of the offered shares have been received for subscription without pre-emptive right.

By reason of the over-subscription, the Board of Directors has resolved on the issuance of 528,041 additional shares to those who have participated in the rights issue in a so-called over-allotment option. Through the rights issue, including the overallotment option, BioInvent will raise SEK 23.2 million before transaction costs.

Cristina Glad, acting CEO and President of BioInvent, comments: ”It is very rewarding for us that our rights issue receive good support from our shareholders and it gives us opportunities to execute the ongoing commercial processes during the second half of 2013, independent of expected revenues from partner projects, and gives us the financial resources to continue our business during that time”.

Those who have subscribed for shares without pre-emptive right will be allotted shares in accordance with the principles outlined in the prospectus, which was published on 3 July 2013. Notifications regarding allotment to those who have subscribed for shares without pre-emptive right are expected to be distributed as from today. Only those who are allotted shares will be notified.

New shares subscribed for are expected to start trading on NASDAQ OMX Stockholm around 6 August 2013.

As a consequence of the rights issue, including the overallotment option, BioInvent will increase its share capital by SEK 887,109.36 to SEK 6,801,171.92. The number of shares will increase by 11,088,867 to 85,014,649 shares.

Redeye acts as financial advisor and Mannheimer Swartling acts as legal advisor to BioInvent in connection with the new issue.

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The Company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Servier. More information is available at www.bioinvent.com.

BioInvent International AB (publ)
Co. reg. No. 556537-7263 
Visiting address: Sölvegatan 41 
Mailing address: 223 70 LUND 
Phone: +46 (0)46 286 85 50 
info@bioinvent.com www.bioinvent.com

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 8.30 a.m. CET, on 25 July 2013.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent International AB.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("Securities Act”) or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend”, "expect”, "anticipate”, "may”, "believe”, "plan”, "estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.

This information was brought to you by Cision http://news.cision.com